The China Chamber of Commerce for Import and Export of Medicines and Health Products has issued a strong rebuke against recent U.S. trade measures, labeling them as "unilateral bullying" that threatens global healthcare access. In a Saturday statement, the industry group representing China's pharmaceutical sector warned that U.S. 'reciprocal tariffs' risk undermining international efforts to protect public health rights.
The chamber emphasized its commitment to "safeguard legitimate rights of global pharmaceutical companies" through coordinated action with international partners. It pledged full support for countermeasures announced by the Chinese government while urging cross-border dialogue to resolve trade disputes.
This development comes as industry analysts observe increased pressure on multinational healthcare supply chains. The chamber noted that unfair trade practices could destabilize pricing structures for vital medications and medical equipment affecting patients worldwide.
